Court Scraps Counterclaims Against J&J Unit

Law360, New York (November 13, 2006, 12:00 AM EST) -- A month after upholding the validity and enforceability of a Johnson & Johnson unit’s patent for the antipsychotic drug Risperdal, a New Jersey district court has thrown out a slew of pending noninfringement and unfair competition counterclaims brought by two generics companies.

The U.S. District Court for the District of New Jersey spared Janssen last week from additional challenges by generic Mylan Pharmaceuticals Inc. and Dr. Reddy’s Laboratories Ltd. to its brand-name drug.

Last month, Judge John C. Lifland approved Janssen’s bid for an injunction against...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.